Download curriculum vitae - UNT Health Science Center

CURRICULUM VITAE
TYLER JAY CURIEL
Home address:
219 Park Hill Drive
San Antonio, TX 78212
Business address:
University of Texas Health Science Center
2040 Babcock Road, suite 201
San Antonio, TX 78229
Telephone:
Fax:
E-mail:
210-562-5287
210-562-5292
[email protected]
PERSONAL HISTORY
Date of birth:
March 31, 1956
Marital status:
Married, two children
UPIN
D3350
Medicare provider number:
4E356
Present positions:
Professor
Department of Medicine
Division of Hematology/Medical Oncology
Citizenship:
American
EDUCATION HISTORY
1977 BS
summa cum laude, with highest honors, with honors in chemistry,
University of Georgia, Athens, GA
1982 MD
Duke Medical School, Durham, NC
1983 MPH
Harvard University, Boston, MA
Internship and Residency:
1983-1984
Intern in Medicine, Yale Medical School and Yale-New Haven Hospital,
New Haven, CT
1984-1986
Resident in Medicine, Yale-New Haven Hospital, New Haven, CT
1
FELLOWSHIPS
1980-1981
Special Research Fellow in Infectious Disease, Duke Medical School,
Durham, NC. Research mentor: Dr. David T. Durack, MD, DPhil
1986-1990
Clinical and Research Fellow in Infectious Diseases, Harvard Medical
School and Massachusetts General Hospital, Boston, MA
1986-1990
Research Fellow in Medicine, Harvard Medical School, Boston. Research
mentors: Drs. Robert Schooley, MD and Bruce Walker, MD
1995-1997
Clinical and Research Fellow in Medical Oncology, University of
Colorado Health Sciences Center, Denver, CO
SPECIALTY CERTIFICATION
1984
1986
1988
1999
Diplomate, American Board of Internal Medicine, number 245997
American Board of Internal Medicine, number 106733
American Board of Infectious Diseases, number 106733
American Board of Medical Oncology, number 106733
LICENSURE
1984
1986
1991
2000
2002
Connecticut State Board of Medical Examiners No. 26470 inactive
Massachusetts State Board of Medical Examiners No. 56080 inactive
Colorado State Board of Medical Examiners
No. 30641
exp 5/31/09
Texas State Board of Medical Examiners
No. L0112
exp 3/31/10
Louisiana State Board of Medical Examiners
No. 14342R exp 3/31/09
PROFESSIONAL POSITIONS
1983
Hospital epidemiologist and attending physician, Hospital Infantil Robert
Reid Cabral, Santo Domingo, Dominican Republic
1983
Attending physician, Pediatric Infectious Disease Division, Hospital
Infantil Robert Reid Cabral, Santo Domingo, Dominican Republic
1985-86
Consultant in Medicine, Gaylord Rehabilitation Hospital, Wallingford, CT
1987-90
Consultant in Medicine, Massachusetts Eye and Ear Infirmary, Boston,
MA
1990
Instructor in Medicine, Harvard Medical School, Boston, MA
2
1990-93
Chief Infectious Disease Consultant, Bone Marrow Transplantation Unit,
University of Colorado Health Sciences Center, Denver, CO
1990-97
Attending physician, Medical Service and Division of Infectious Diseases,
University of Colorado Health Sciences Center, Denver, CO
1990-97
Attending physician, Division of Infectious Diseases, Veterans' Affairs
Medical Center, Denver, CO
1990-96
Chairperson, Infection Control, University Hospital, Denver, CO
1990-97
Assistant Professor of Medicine (Infectious Diseases), University of
Colorado Health Sciences Center, Denver, CO
1992-94
Assistant Director for Basic Science Research, Bone Marrow
Transplantation Unit, University of Colorado Health Sciences Center,
Denver, CO
1992-94
Director, Core Human Immunology Laboratory, Cancer Center University
of Colorado Health Sciences Center, Denver, CO
1993-97
Assistant Professor of Immunology, University of Colorado Health
Science Center Graduate School of Immunology, Denver, CO
1995-97
Assistant Professor of Medical Oncology, University of Colorado Health
Sciences Center, Denver, CO
1996-97
Program co-Director, and Basic Science Director, AIDS-Related
Malignancy Program, UCHSC Cancer Center, Denver, CO
1997-2001
Associate Investigator, Baylor Institute for Immunology Research, Dallas,
TX
1998-
Associate Professor, Graduate Program in Biomedical Sciences, Baylor
University, Waco, TX
2001-2003
Associate Professor of Medicine, Tulane University School of Medicine
School, New Orleans, LA
2001-
Section Chief, Hematology and Medical Oncology, Tulane University
School of Medicine, New Orleans, LA
2001-
The Henderson Chair in Medicine, Tulane University School of Medicine,
New Orleans, LA
3
2002-2003
Associate Professor of Cell and Molecular Biology, Tulane University,
New Orleans, LA
2002-2003
Clinical Associate Professor of Obstetrics and Gynecology, Tulane
University School of Medicine School, New Orleans, LA
2001-2003
Associate Professor of Medicine with tenure, Tulane University School of
Medicine School, New Orleans, LA
2003-2006
Professor of Medicine with tenure, Tulane University School of Medicine
School, New Orleans, LA
2003-2006
Clinical Professor of Obstetrics and Gynecology, Tulane University
School of Medicine, New Orleans, LA
2003-2006
Professor of Cell and Molecular Biology, Tulane University, New
Orleans, LA
2005-2006
Director, Tulane/LSU General Clinical Research Center, Medical Center
of Louisiana (Charity Hospital) and Tulane University, New Orleans, LA
2005-2006
Visiting Clinical Professor of Medicine and Member, University of
Colorado School of Medicine, Denver, CO and the Anschutz Cancer
Center, Aurora Colorado
8/2006-
Adjunct Professor of Medicine, Tulane Medical School
8/2006-12/07 Director, San Antonio Cancer Institute
UTHSCSA
8/2006-12/07 Scientific Director
Center for Treatment & Research on Cancer
San Antonio, TX
8/2006-3/2007 Interim Chief, Division of Medical Oncology
University of Texas Health Sciences Center
8/2006-
Dielmann Professor of Medicine
University of Texas Health Sciences Center San Antonio (UTHSCSA)
8/2007-
Max and Minnie Tomerlin Voelcker Distinguished University Professor of
Targeted Cancer Therapy, UTHSCSA
8/2006-
Assistant Dean for Oncology, UTHSCSA
12/07-2/08
Director, Cancer Therapy & Research Center at the UTHSCSA
4
UTHSCSA
2/08-10/09
Executive Director, Center for Cancer Therapy & Research, UTHSCSA
2/08-10/09
Scientific Director, Center for Cancer Therapy & Research, UTHSCSA
AWARDS AND HONORS
1974
1977
1977
1977
1977
1979
1981
1996
1996
2001
2002
2002
2002
2003
2003
2003
2003
2004
2004
2004
2004
2005
2005
Gordon P. Watson Award (Outstanding Freshman)
Honors Graduate in Chemistry
Phi Beta Kappa
Phi Kappa Phi
Sigma Xi
Lane Memorial Scholarship (Duke)
Alpha Omega Alpha Honor Medical Society
Certificate of Commendation from the Medical Staff, University of
Colorado Health Sciences Center
Certificate of Commendation from Hospital Administration, University of
Colorado Health Sciences Center
Research chosen for the cover of the 2001 Tulane Medical School Annual
Research Report
Focused Giving Award recipient, Johnson and Johnson Corporation
Picture chosen for the cover of the 2002 Tulane Health Sciences Center
Annual Report
Bouquet Award for civic service from The Gambit weekly newspaper of
New Orleans, LA
Research chosen for the cover of the 2003 Tulane Medical School Annual
Research Days Program Book
Mauvernay Research Excellence Award (includes $500 prize) from
Tulane University
Featured person in Living section of the New Orleans Times-Picayune
newspaper. August 9, 2003, page E1.
Bouquet Award for civic service from The Gambit weekly newspaper of
New Orleans, LA
Featured person in “Random Samples”. Science. 2004;303:37.
Featured person in La Prensa. Spanish language newspaper of Louisiana
area. February 2004, p. 30-34.
New Orleans Business Innovator of the Year Honorable Mention (shared
with Andy Martin for co-founding Bounce for LifeTM non-profit cancer
research organization)
Mauvernay Grand Prize for Cancer Research from Tulane University.
(Includes a $5000 award).
New Orleans Business Innovator of the Year (shared with Andy Martin
for co-founding Bounce for LifeTM non-profit cancer research
organization)
Leonard Tow Humanism in Medicine Award from Tulane Medical School
5
2005
2006
2006
2006
Inductee, Arnold P. Gold Foundation for Humanism in Medicine
Bouquet Award for civic service, The Gambit Weekly, New Orleans, LA
Featured scientist, NovaNow Science Programs, Public Broadcasting
System
STARS Research Enhancement Award from the University of Texas
System
PROFESSIONAL SERVICE AND COMMITTEES
Institutional and Departmental:
1991-95
1992-95
1997-2001
2001
200120012001-
20012002200220022003
2003
2003
2003
2003
2003
20032003
2003
2005
2005
2006
2006
2006
Drug Utilization and Evaluation Committee
Women in Medicine Committee
Biosafety Officer, Baylor Institute for Immunology Research
Baylor Institutional Animal Care and Utilization Committee
Tulane Cancer Center Steering Committee
Tulane Medical Center Internship and Residency Selection Committee
Tulane Medical School MD/PhD Program, Admissions Committee
Steering Committee for the Cancer Research Consortium of Louisiana at
New Orleans
Member, Cancer Research Advisory Board, Tulane Cancer Center
Tulane Hospital Cancer Committee member
Tulane Cancer Center Site Leaders, Chairman of Immunotherapy Group
Tulane Cancer Center, Program Leader for Phase I/II Studies
Louisiana Cancer Research Consortium at New Orleans, Director of
Program in Immunology, Tulane component
Member, Search Committee for Associate Senior Vice President or
Research, Tulane University
Co-Moderator, Poster Discussions for Tulane Research Days
Research Judge, Tulane Annual Research Days Program
Member, Pulmonary Chief Search Committee, Tulane Medical School
Member, Search Committee for Associate Vice President AVP for
Technology Transfer and Business Development, Tulane University
Chair, Infectious Diseases Chief Search Committee, Tulane University
Treasurer, Alpha Omega Alpha Honor Medical Society, Tulane Chapter
Development Committee, The TUHSC Auxiliary Award for Excellence in
Research
Development Committee, Charles B. Henriques Award for Excellence in
Research
Tulane Research Space Committee
Member, Pediatrics Chairman Search Committee, Tulane Medical School
Member, Faculty Compensation and Incentive Plan Committee, Tulane
Medical School
Member, Research Evaluation and Strategic Plan Committee, Tulane
Medical School
Member, South Texas Research Facility Planning Committee, UTHSCSA
6
2007
2008
Member, chief of surgical oncology search committee, UTHSCSA
Member, search committee, dean of the graduate school of biomedical
sciences, UTHSCSA
Regional:
20022002-
Abstract Reviewer, Southern Society of Clinical Medicine Regional
Meetings
Member, SWOG Immunomolecular Therapeutics Committee
National:
1993-96
1993-96
2008-2010
Vice Chairperson, Cellular Immunity Working Group, AIDS Clinical
Trials Group (ACTG)
Ad Hoc Member, NK Cytotoxicity Quality Assurance and Assay
Standardization Committee, (ACTG)
Member, Scientific Program Committee in Developmental TherapeuticsImmunotherapy, ASCO
International:
2002-2004
Planning Committee, 2004 International Society for Experimental
Hematology International Meeting, New Orleans, LA. July 2004.
PATENTS
1. "Compositions and Method for Inhibition of HIV Production." G. S. Harrison,
I. H. Maxwell, T. J. Curiel and F. Maxwell. This patent describes the concept of HIVregulated diphtheria toxin A subunit as an HIV gene therapy, and describes technical
details related to expression cassette design and production. U.S. patent number
5,554,528. Issued 9/93.
2. “Inhibition of Toxoplasma gondii replication by pyridinylimidazoles”. T. J.
Curiel. This application describes the actions of pyridinylimidazoles on the inhibition of
growth of medically important intracellular parasites. Patent 6,649,637 issued November
18, 2003.
3. Composition of dendritic cell binding peptides. T. J. Curiel, C. Morris, M.
Zadeh. This application describes novel 12-mer peptides that specifically bind to
Langerhans dendritic cells or to interstitial dendritic cells. They are useful for vaccines,
and to isolate dendritic cells. Provisional patent filed 4-03. Full application filed 4-04.
REVIEW AND REFEREE ACTIVITIES
Grants
7
Local:
1993
Internal grant reviewer, Gene Therapy Core, Cancer Center, University of
Colorado Health Sciences Center, Denver, CO
2002- Internal grant reviewer, Tulane Cancer Brown Endowment Matching
Grants, Tulane University School of Medicine, New Orleans, LA
2003 Tulane Research Days research judge
State:
2002-2006
Louisiana State Task Force on Bioterrorism
Regional:
2003-2006
meeting
Southern Society for Clinical Investigation abstract reviewer for
National:
1997
NIAID Novel AIDS Vaccines Initiative ad hoc
1997-2001
Veteran's Affairs MERIT Grants
1998
NHLBI Immune Defenses in Pulmonary Infections ad hoc
2001
NIAID PA-01-075 Mucosal HIV infection ad hoc
2002
NCI SRG-Subcommittee C, Basic and Preclinical Sciences (P30
Program) ad hoc
2003
NCI SRG-Subcommittee C, Basic and Preclinical Sciences (P30
Program) ad hoc
2003
NIH Experimental Immunology Study Section ad hoc
2003
NIH AITC (P30 Program) Tumor Immunology ad hoc
2003
NIH NIAID ZRG1 SSSF (01) Special Emphasis Panel on AIDSrelated Infections ad hoc
2004
ZAI1 KS-I (J1) Special Emphasis Panel/Initial Review Group for
cancer P01 ad hoc
2005
COI (C) Special Emphasis Panel/Initial Review Group for HCV
Center of Excellence U19
8
2005
Congressionally Directed Medical Research Programs in Ovarian
Cancer
2005
External Reviewer for Morehouse School of Medicine Minority
Biomedical Research Support Program
2006
Ad hoc reviewer, NIAID ACTU initiatives Special Emphasis Panel
ZAI1 MPM-A-M1
2006
Ad hoc reviewer, NIAID ACTU initiatives Special Emphasis Panel
ZAI1 SR-A-M3
2006-
Ad hoc reviewer, NCI, Tumor Microenvironment (TME) Study
Section
2008
Ad hoc reviewer, NCI, Cancer Center Review Panel
2008
Ad hoc reviewer, DARPA, prostate cancer grants
Journals
Ad Hoc Reviewer:
AIDS
AIDS Newslink
AIDS Research Human Retroviruses
American Board of Internal Medicine
(Subspecialty Boards in Medical Oncology)
American Journal of Pathology
Ashley Publications (Immunology Reviews)
Bone Marrow Transplantation
British Medical Journal
British Journal of Cancer
Cancer Research
Cellular Immunology
9
Cellular and Molecular Immunology
Clinical Cancer Research
Clinical and Experimental Immunology
Clinical Immunology
Clinical Immunology and Immunotherapy
Clinical Microbiology Reviews
Contemporary Oncology
Elsevier Publications Books
Haematologica
International Journal of Cancer
International Journal of Parasitology
Journal of Clinical Investigation
Journal of Immunology
Journal of Infectious Diseases
Journal of Leukocyte Biology
Journal of Molecular and Cellular Biology
Microbes and Infection
Nature Reviews Cancer
Nature Reviews Immunology
New England Journal of Medicine
Parasitology Today
Perspectives
Proceedings of the National Academy of Sciences (USA)
10
Tumor Targeting
Editorial Boards:
Frontiers in Bioscience 1998-2003
Tumor Targeting
1999-2003
Associate editor, Journal of Immunology 2005Editorial Board, Clinical Medicine: Oncology 2007-
PROFESSIONAL ASSOCIATIONS
American Association of Immunologists member #208840
American Association for the Advancement of Science #03161226
Southwest Oncology Group
American Society of Clinical Oncology member #37686
American Society for Hematology member
American Association of Cancer Research member #124869
Gynecologic Oncology Group
Southern Society of Clinical Investigation
European Society of Gynaecologic Oncology member #0560
European Society for Cancer Immunology and Immunotherapy
TEACHING ACTIVITIES
Graduate and Medical School Lectures:
1983
Lecturer, Public Health, Epidemiology, Statistics and Immunology,
Universidad Mundial, Santo Domingo, Dominican Republic
1989
Lecturer, Harvard School of Public Health, Divisions of Maternal Studies
and Population Science, Boston, MA
11
1990
1990-97
Lecturer, Infectious Diseases, Postgraduate Course, Massachusetts
General Hospital/Harvard Medical School, Boston, MA
Lecturer, Health Professionals Continuing Medical Education, University
of Colorado Health Sciences Center, Denver, CO
1990-97
Lecturer, Infectious Disease Pathophysiology Course for second year
medical students, University of Colorado Medical School, Denver, CO
1990-97
Designated speaker for the Infection Control Committee to Housestaff. I
gave lectures on Infection Control-related issues to all incoming
housestaff yearly at orientation, and topic-specific seminars throughout the
year on an as-needed basis.
1992-97
Lecturer, IDPT 7664, a graduate seminar "Immune responses to infectious
agents and immunopathology." The Graduate School of Microbiology and
Immunology, University of Colorado, Denver, CO
1998-2001
Research Mentor, University of Texas Waco Program in Biologic
Sciences. Rotating lectures in Immunology and Microbiology to the
graduate students. Allow graduate students to rotate through my
laboratory.
2000-2001
Graduate seminar in immunology lecturer at Baylor University. Gave
immunology lectures to first and second year graduate students in
Biomedical sciences.
2002-
Graduate seminar in tumor immunology at Tulane Medical School. This is
a special seminar for graduate students in the Program in Cell and
Molecular Biology, and the School of Public Health.
2003
Lectures to Tulane second year medical students in leukemias and
lymphomas
2004
Lecture to LSUHSC-NO graduate students in MIP Program on tumor
immunology. March 22 and March 26, 2004.
2006
Immunology lecturer, National Jewish Center for Immunology and
Pulmonary Diseases, Denver, CO. A series of lectures to graduate students
in the immunology program.
2008-
Immunology lecturer, UTHSCSA graduate school in biomedical sciences.
Micr 5003/5027: Fundamental Concepts in Microbiology and
Immunology
Premedical Student Preceptor:
12
1992-97
Preceptor and lecturer, NIH Minority Student Enrichment Program. This
program is for college level students wishing to pursue a career in
biomedical sciences. Responsibilities include giving one lecture (on HIV
disease), and acting as research preceptor for a student rotating through the
lab.
1993-97
Preceptor and lecturer, minority high school student program. This is
essentially the same program as above, designed for high school students.
2002
Preceptor for Xavier University (New Orleans) summer internships for
minority students interested in biomedical careers. Students rotate through
our laboratories and do hands-on work.
2002-2006
Immunology preceptor of Tulane undergraduate students
Medical Student Preceptor:
1986-1990
Preceptor, Introduction to Clinical Medicine, a course for second year
Harvard medical students. I provided hands-on clinical examination
exercises for groups of four students.
1991-97
Oral final exam preceptor for third year University of Colorado Health
Sciences Center medical students completing the required General Internal
Medicine rotation.
2002-2006
Introduction to Clinical Diagnosis. Physical diagnosis and history taking at
the bedside for Tulane Medical School, second year students.
2003-2006
Clinical Decision Making Journal Club. A small group forum for
discussing medical literature and how to interpret study design for secondyear Tulane Medical students.
2003-2005
Preceptor for medical students in the Tulane Medical School summer
research fellowship.
2004-2006
Clinical Mentorship program mentor for Tulane Medical students
2004 students: Sukhwant Singh, T-3 ; Lena J. Gamble, T-2;
Jason Prior, T-2.
Graduate Student Preceptor:
1992-1996
Research advisor and rotating laboratory experience mentor to graduate
students, the Graduate Program in Immunology, University of Colorado
Health Sciences Center, Denver, CO
13
1993-97
Research advisor, Infectious Disease fellowship training program, the
Children's Hospital and University of Colorado Health Sciences Center,
Denver, CO
2000-2007
Research advisor and rotating laboratory experience mentor to graduate
students, the Graduate Program in Biomedical Sciences, Baylor
University, Waco, TX
2001-2003
Thesis committee, Stephanie Carmichael, PhD candidate, Tulane Graduate
School (Biochemistry). “The influence of antigen three-dimensional
structure on helper T cell epitope immunodominance” PhD awarded April
2003.
2003-2005
Thesis committee, Margaret Parks, PhD candidate, Tulane Graduate
School (Genetics). “Apoptosis in cystinosis”. PhD awarded June 2005.
2007-
Thesis advisor, Suzanne Thibodeaux, candidate for PhD, UTHSCSA.
“The role of B7-H1 signals in cancer”
2007-
Thesis advisor, Pei Yi Lin, candidate for PhD, UTHSCSA. “Non-Treg
regulatory cells in cancer”.
Former Trainees:
Elizabeth McFarland, MD 9/90-8/91
Project: CTLs in pediatric HIV infection
Position: post-doctoral Infectious Disease Fellow, UCHSC
Current position: Assistant Professor of Pediatrics, UCHSC. Assistant Director,
Immunodeficiency Clinic, the Children's Hospital, Denver, CO.
Pascal Poignard, PhD 11/90-10/91
Project: cellular immunity to T. gondii
Position: visiting scientist, UCHSC Infectious Disease Division
Current position: Scientist, Torrey Pines Research Institute, La Jolla, CA
Elizabeth Connick, MD 7/91-6/94
Project: immune responses in acute HIV infection
Position: post-doctoral Infectious Disease Fellow, UCHSC
Current position: Associate Professor of Medicine, University of Colorado Health
Sciences Center, Denver, CO
Paul Nash, PhD 1/94-10/96
Project: apoptosis in T. gondii infected cells; animal vaccine models.
Position: post-doctoral fellow in Immunology, Graduate Program in Immunology,
University of Colorado, Denver, CO.
Current position: Research Scientist, Heska, Inc., Ft. Collins, CO
14
Penelope Clarke, PhD 2/96-9/97
Project: development of recombinant T. gondii; cloning novel T. gondii genes
Position: Research associate, UCHSC
Current position: unknown
Myra Morgan, MD 8/95-6/98
Project: role of EBV in B cell lymphomas, immunity in bone marrow transplant
Position: Infectious Disease Fellow, UCHSC
Current Position: Associate Professor of Medicine
University of Michigan Medical Center, Ann Arbor, MI
Tatyana Isaeva, MD, PhD 7/99-7/01
Project: Myeloid dendritic cells in ovarian and other carcinomas
Position: junior research fellow, BIIR
Current Position: Staff Scientist, UAB Gene Therapy Program, Birmingham, AL
Weiping Zou, MD, PhD 3/99-8/01
Project: Differentiation of myeloid and lymphoid human dendritic cells in cancer
Position: post-doctoral fellow, BIIR
Current Position: Associate Professor of Medicine with tenure, Tulane Medical
School
Charlie Branson, BS 6/00-8/00 and 12/00-8/01
Project: SDF-1 and T cell immunity in ovarian carcinoma
Position: candidate for MS, UT Waco
Current Position: unknown
Hania Wehbe, BS 6/01-8/01
Project: immunity to ovarian carcinoma
Position: candidate for PhD, UT Waco
Current Position: candidate for PhD, UT Waco
Carla Zimmerman, BS
6/02-1/03
Project: DCs in ovarian cancer
Position: graduate student, Tulane
Shuang Wei, PhD 6/99-12/03
Senior post-doctoral fellow, Tulane Medical School
Project: Regulation of differentiation of human dendritic cells
Current position: Instructor in Medicine, University of Michigan
Michael Brumlik, PhD
4/03-12/03
Project: cloning of a novel T. gondii MAP kinase
Position: Research Associate
Current Position: Assistant Professor of Medicine, tenure track, UTHSCSA
15
Joel Greco
3/03-5/03
Tulane PhD candidate. B7-H1 regulation in Toxoplasma gondii infection.
Current position: Tulane PhD candidate
Erin Coakley 9/02-5/03
Tulane Medical student. Role of SDF-1 in ovarian cancer pathogenesis.
Current position: intern in medicine, Tulane Medical School
Jason Prior
6/03-8/03
Tulane Medical student, second year
B7-H1 signals in Toxoplasma infection
Current position: medical student, Tulane medical school
Janis Taube, MS 6/03-12/03
Tulane fourth year medical school student
Immunologic effects of nucleated red blood cells
Current position: Junior resident in Pathology, Johns Hopkins
Charla Poole 6/03-8/03
Tulane Medical School MD, PhD student
Estrogen signals in dendritic cell dysfunction
Current position: MD/PhD student, Tulane
Alexander Hillel 9/03-4/04
Tulane fourth year medical school student
CD40 signals in cancer pathogenesis
Current position: Junior resident in ENT surgery, Johns Hopkins
Kirshma Kehmani
9/03 to 5/04
Tolerance to BMT
Current position: Medical Student, St. Georges
Andrew Martin 9/03-8/04
Tulane second year medical school student
studies of sinonasal undifferentiated carcinoma
Current position: deceased
Nikki Singh
Tulane senior medical student
Regulatory T cells in ovarian cancer
Current position: resident in Medicine, Oregon Health Sciences Center
Marisa Toups
Tulane senior medical student
studies of sinonasal undifferentiated carcinoma
16
Current position: intern in surgery, UAB
Rahul Dalvi, MD
7/04- 6/05
Post-doctoral fellow
Studies of sinonasal undifferentiated carcinoma
Current position: resident in medicine, LSU-NO
Rachael Yenni
9/04- 8/05
Tulane University senior undergraduate student
Role of a novel T. gondii MAP kinase in virulence
Current position: PhD candidate, Tulane Graduate School
Suzanne Thibodeaux
9/02-6/05
Tulane undergraduate student
Regulation of B7-H1 in T. gondii infection
Current position: MD/PhD student, UTHSCSA
Rebecca Kruse-Jarres, MD 5/05Hematology and Medical Oncology fellow
Tolerance to factor VIII in hemophilia
Current position: Clinical Assistant Professor of Medicine (Heme/Onc)
Tulane Medical School
Holly Murphy, MD 5/05-3/08
Regulatory T cells in HIV pathogenesis
Current position: Instructor in Medicine, Tulane Medical School
K23 mentee
Brian Barnett, MD 7/03-12/05
Post-doctoral fellow, Tulane Medical School
Immunopathogenesis of ovarian cancer
Current position: Assistant Professor of Medicine (Heme/Onc), Tulane Medical
School
Ben Daniels, BS
6/00-8/00 and 5/01- 5/05
Project: immunity to Toxoplasma gondii
Position: candidate for PhD, UT Waco (lab work at Tulane)
Current position: instructor of medicine, UTHSCSA
Alexander Gelbard, BS 7/05-7/06
Senior Tulane medical student
Regulatory T cells in head and neck cancers
Current position: intern in ENT surgical oncology, Baylor Medical School
Ben Daniel, PhD
5/05-6/07
Project: novel means to deplete regulatory T cells in cancer
17
instructor of medicine, UTHSCSA
Jens Reuter, MD
8/05-6/07
Fellow, Hematology and Medical Oncology
Immunopathogenesis of ovarian cancer
Current position: fellow in medical oncology, University of Pennsylvania
Rachael Yenni
6/05-6/07
PhD candidate, Graduate Program in Biomedical Sciences
Tulane Medical School
Novel methods to deplete T regulatory cells
Current position: PhD candidate, Graduate Program in Biomedical Sciences (lab
change)
Current Trainees:
Suzanne Thibodeaux, BS
Position: MD/PhD student
Project: “The role of B7-H1 signals in cancer”
Pei Yi Lin, BS
Position: PhD student
Project: “Non-Treg regulatory cells in cancer”.
GRANTS, CONTRACTS AND AWARDS
Current:
NCI 5R01 CA105207 “Plasmacytoid dendritic cell behavior in ovarian cancer”. My role:
PI 15.1%. $1,856,250. 7/15/05 to 6/30/11.
FDA R01 FD003118 “Phase II trial of Ontak to treat ovarian cancer under BB-IND
312345”. My role: PI 10% effort. $1,050,000 requested 3/15/06 to 3/14/10
NIH 5R01 AI060424 “A novel MAPK family in T. gondii.” PI: T. Curiel. 10% effort.
$1,485,000 4/01/05 to 4/30/11.
3R01 CA105207-02S1 Plasmacytoid dendritic cell behavior in ovarian cancer. PI: Curiel,
Tyler J. MD Project Period: 07/27/2005 - 04/30/2010 $151,981
5P30CA54174-16S2. San Antonio Cancer Institute. Role: PI. 6/30/92-6/30/08.
$2,700,000
Rippel Foundation “Novel studies of Treg depletion in ovarian cancer”. $270,000 3/06 to
3/08. Role: PI: 2% effort.
18
STAR Award no number “Development of novel immunotherapies for cancer”.
$1,250,000 12/06 to 12/07. My role: PI.
Clavis Pharmaceuticals. A Phase I/II Study of CP-4055 in Patients with Platinum
Resistant Ovarian Cancer. PI: T. Curiel.
AG013319-15 “Immune dysregulation in aged hosts with cancer.” PI: Curiel, Tyler J.
MD Project Period: 4/01/10 – 3/31/13 $1,359,177
Supplement to NIA Barshop Institute “Support Immune effects of rapamycin”. PI: Curiel,
Tyler J. MD Project Period: 7/15/09 – 7/14/10 $32,500
Eisai Pharmaceuticals Phase II trial of Ontak plus interferon-α for ovarian cancer. PI:
Curiel, Tyler J MD Project Period: 9/01/09 – 8/30/14 $66,000
1 RC2 AG036613-01 “Can Rapamycin Retard Age-Related Diseases.” $225,000
Pending:
None
Previous:
1. 10/87-9/89 National Research Service Award. Cellular immunity in HIV disease. PI:
T. Curiel. Mentor: R.T. Schooley. $95,000.
2. 10/92-6/94 CellPro, Inc. "Immune reconstitution following CD34+ autologous stem
cell transplantation." PI: T. Curiel $42,000
3. 9/91-6/94 Immune Response Corp. "CMI to a candidate HIV immunogen". PI: T.
Curiel. $280,000
4. 12/92-1/94 Repligen Corp. "Testing of potential HIV vaccines in mice" PI: T. Curiel.
$32,000
5. 11/92-2/95 Supplement to 5P30CA-46934. "Immune therapies for B-cell lymphomas"
PI: T. Curiel. $117,900
6. 5/92-12/96 NCI R01 AI 27096-04A2 "Toxin gene therapy for AIDS" PI: G.S.
Harrison. My role: investigator. $1,300,000.
7. 8/93-9/97 NIAID N01 AI 15123 "Immune studies support for DATRI 002" (CMI in
acute HIV infection). PI: T. Curiel. $344,960.
8. 1/94-12/96 NIH 1 U01 AI35231-01. Efficient delivery of HIV-regulated toxin genes
for AIDS. PI: G. Harrison. My role: Project leader for SCID mouse and CD34+ stem cell
facility. $426,601.
19
9. 3/95-3/98 NCI CA67396-01 "Treatment of AIDS lymphomas with EBV antisense
oligos." Role: Co-PI. $1,200,000.
10. 9/96-9/97 NCI. Supplement to 5P30CA-46934. "sFv as gene therapy for AIDS
related lymphomas". Role: PI. $75,000.
11. 12/96-11/98 Ligand Pharmaceuticals. "Phase II/III trials of Targretrin in cutaneous T
cell lymphoma." My role: PI. $75,000.
12. 10/95-10/97 Amgen, Inc. "Immune support for SCF 940190. “Autologous stem cell
support of high dose chemotherapy for breast cancer”. My role: PI. $200,000.
13. 4/1/99-4/1/00 CA78846-01. Subpopulations of human dendritic cells. PI: J.
Banchereau, $1,222,286. My role: Investigator (10%).
14. 9/97-8/01 Baylor Research Institute Endowment. My role: PI. 28% effort "Dendritic
cells and activation of human T cells". $1,5300,000.
15. 11/95 to 10/02 NIH R01 AI39379 "Human cellular immunity to T. gondii" My role:
PI. 35% effort. $1,033,000.
16. 7/01-7/02. DAMD 17-01-1-0479. “The role of the immune cell cytoskeleton in
breast cancer immunity: particular relationship between actin and p38 MAP kinase.” My
role: mentorPI. $75,000.
17. American Medical Association. “Immunologic consequences of nucleated red blood
cells.” Mentor for Janis Taube, Tulane Medical student. $2450. 8/02-12/02
18.American Medical Association. “Role of IL-15 in immunopathogenesis of cutaneous
T cell leukemia/lymphoma.” Mentor to Abita Taher, PhD, Tulane Medical Student.
$2500. 10/02-2/03.
19. 12/1/01-12/1/03 Golfers against Cancer. “Macrophages and tumor-specific
immunity.” My role: PI. 1% effort. $50,000.
20. Alpha Omega Alpha. “Immunologic consequences of nucleated red blood cells.”
Mentor for Janis Taube, Tulane Medical student. $3500. 3/03-12/03.
21. American Medical Association. “CD40 expression in cancer immunopathogenesis”
Mentor to Alexander Hillel, Tulane Medical Student. $2500. 3/03-12/03.
22. 5/00 to 4/03 NIH R21 AI44322 “DCs and HIV immunity.” $507,000. My role: PI.
20% effort.
20
23. 5U01 CA83014-04 “Tulane AIDS Malignancy Consortium.” PI: E. Zakris. My role:
co-investigator. 10% effort. $350,000. 8/1/02 to 7/31/04.
24. Cancer Association of Greater New Orleans. “Biology and immunology of sinonasal
undifferentiated carcinoma”. $7500. January 2004 to January 2005. My role: PI.
25. NIH 5R21 DA016029 “Dendritic cell targeted hepatitis C virus treatment”.
PI: T. Curiel 5% effort. $510,000. 9/1/02 to 8/31/05.
26. Johnson and Johnson, Inc. “Local delivery of anti-neoplastic agents”. $125,000 3/04
to 3/06. PI: T. Curiel. 2.5 % effort.
27. NCRR M01 RR05096 “Tulane General Clinical Research Center”. PI: T. Curiel. 25%
effort. $13,843,595 total direct costs 12/01/01 to 11/30/06.
28. NCI 5R01 CA107974 “Arginase production in cancer: evading immune response” PI:
A. Ochoa. My role: co-investigator 2%. $1,4850,000 10/01/04-9/30/09
29. NCI 5R01 CA100425 “SDF-1/CXCR4 signals in ovarian cancer”. PI: T. Curiel. 10%
effort. $1,450,000 7/01/04-6/30/09.
CLINICAL TRIALS
IND holder. PSA vaccine for prostate cancer. 7/00 to 8/03. A clinical trial
underwritten by Jenner Biotherapeutics.
Principal Investigator. Phase I/II Trial of Ontak to improve tumor immunity in
patients with cancer. 9/25/03Ontak and cancer: BB-IND#11560
Ontak and HCV: BB-IND#11602 (on clinical hold)
Phase II trial of Ontak in ovarian cancer: BB-IND#12345
Principal Investigator. Phase II Trial of Ontak to treat refractory epithelial ovarian
cancer. 8/10/05Principal Investigator: Phase II trial of PanVac plus Ontak in refractory ovarian
cancer. Trial under development with NCI (James Gulley and Jeff Schlom) and
Therion Biologics (Dennis Panacali)
BIBLIOGRAPHY
Scientific manuscripts:
21
1.
Curiel TJ, Perfect JR and Durack DT. Leukocyte subpopulations in cerebrospinal
fluid of normal rabbits. Laboratory Animal Science. 1982;32:622-24.
2.
Chao BH, Costopoulos DS, Curiel TJ, Bertonis JM, Chisholm P, Williams C,
Schooley RT, Rosa JJ, Fisher RA and Maraganore JM. A 113-amino acid
fragment of CD4 produced in Escherichia coli blocks human immunodeficiency
virus-induced cell fusion. J Biol Chem. 1989;264:5812-5817.
3.
Leff JA, Oppegard MA, Curiel TJ, Brown KS, Schooley RT and Repine JE.
Progressive increases in serum catalase activity in advancing Human
Immunodeficiency Virus infection. Free Radical Biology & Medicine.
1992;13:143-149.
4.
Harrison GS, Long CJ, Curiel TJ, Maxwell F and Maxwell I. Inhibition of
Human Immunodeficiency Virus-1 (HIV-1) production resulting from
transduction with a retrovirus containing an HIV-regulated diphtheria toxin A
chain gene. Human Gene Therapy. 1992;3:461-469.
5.
Curiel TJ. Tuberculosis in HIV infection. AIDS Newslink. 1992.
6.
Curiel TJ, Wong JT, Gorzcyca PF, Schooley RT and Walker BD.
CD4+ Human immunodeficiency virus type 1 (HIV-1) envelope-specific
cytotoxic T lymphocytes derived from the peripheral blood cells of an HIV-1
infected individual. AIDS Research and Human Retroviruses. 1993;9(1):61-68.
7.
McFarland E, Curiel TJ, Rosandich ME, Schoen DJ, Schooley RT and Kuritzkes
DR. Cytotoxic T lymphocyte lines specific for Human Immunodeficiency virus
type I gag and reverse transcriptase derived from a vertically infected child.
Journal of Infectious Diseases. 1993;167(3):719-723.
8.
Curiel TJ, Purner MB, Poignard P, Krug EC and Berens RL. Cloned human
CD4+ cytotoxic T cells specific for Toxoplasma gondii lyse tachyzoite-infected
target cells. J Immunol.1993;151(4):2024-31.
9.
Curiel TJ. Risks of Toxoplasmosis to women. Perspectives 1993;1(1):13-14.
10.
Shpall EJ, Jones RB, Franklin W, Curiel T, Bitter M, Claman H, Archer P,
Bearman SI, Stemmer SM, Myers S, Hami L, Johnson C, Taffs S, Heimfeld S,
Hallagan J and Berenson RJ. Transplantation of autologous CD34+ hematopoietic
progenitor cells into breast cancer patients following high-dose chemotherapy:
Influence of cell source and growth factors on engraftment. J Clin Oncology.
1994;12(1):28-36.
11.
Curiel TJ, Nicot D, Wang Y, Ghosh S, Hahn B and Harrison G. Long-term
inhibition of clinical and laboratory HIV-1 isolates with a retrovirus encoding an
22
HIV-regulated diphtheria toxin A chain gene. Human Gene Therapy.
1993;4(6):741-747.
12.
Curiel TJ, Nicot D, Bogedain C, Jilg W, Harrison GS, Cotton M, Curiel DT and
Wagner E. Efficient foreign gene expression in Epstein-Barr virus transformed
human B-cells. Virology. 1994;198:577-585.
13.
Purner MB, Krug EC, Berens RL and Curiel TJ. Epstein-Barr virus transformed
B-cells: a potentially convenient antigen presenting cell for propagation of certain
human cytotoxic T-cells. Clinical and Diagnostic Laboratory Immunology.
1994;1(6), 696-700.
14.
Cook DR, Maxwell IH, Glode LM, Maxwell F, Stevens JO, Purner M, Wagner E,
Curiel DT and Curiel TJ. Gene therapy for B-cell lymphoma in a SCID mouse
model using an immunoglobulin-regulated diphtheria toxin gene delivered by a
novel adenovirus vector. Cancer Biotherapy. 1994;9(2):131-41.
15.
Roth G, Curiel TJ, Lacy J. Epstein-Barr viral antigen 1 (EBNA 1) antisense
oligonucleotide inhibits proliferation of Epstein-Barr virus-immortalized B cells.
Blood. 1994;84(2):582-587.
16.
Purner MB, Krug EC, Nash P, Cook DN, Berens RL and Curiel TJ. Crossreactivity of Human Toxoplasma-specific T Cells: Implications for development
of a potential immunotherapeutic or vaccine. J Inf Dis. 1995;171(4):984-991.
17.
Finkel TH, Tudor-Williams G, Banda NK, Cotton MF, Curiel TJ, Monks C and
Kuper A. Apoptosis occurs in bystander cells and not in productively infected
cells of HIV-infected lymph nodes. Nature Medicine. 1995;1:129-134.
18.
Harrison GS, Wang Y, Tomczak J, Hogan C, Shpall EJ, Curiel TJ and Felgner
PL. Optimization of gene transfer using cationic lipids in cell lines and primary
human CD4+ and CD34+ hematopoietic cells. BioTechniques. 1995;19(5):816823.
19.
Dinges MM, Cook DR, King J, Curiel TJ, Zhang X-Q and Harrison GS. HIVregulated diphtheria toxin A chain gene confers long-term protection against HIV
type 1 infection in the human promonocytic cell line U937. Human Gene
Therapy. 1995;6:1437-1445.
20.
Connick E, Zhang X-Q, Clark SJ, Saag MS, Schooley RT and Curiel TJ. HIVspecific cellular and humoral immune responses in primary HIV infection. AIDS
Res Human Retro. 1996;12(12):1129-1140.
21.
Purner MB, Berens RL, Nash PB, Ross E, van Linden A, Kruse C, Krug EC and
Curiel TJ. CD4-mediated and CD8-mediated cytotoxic and proliferative immune
23
responses to Toxoplasma gondii in seropositive humans. Infection & Immunity
1996;64(10):4330-4338.
22.
Banda NK, Tomczak JA, Shpall EJ, Sipple J, Steimer K, Hami L, Curiel TJ, and
Harrison GS. HIV-gp120 induced cell death in hematopoietic progenitor CD34+
cells. Apoptosis 1997;2:61-68.
23.
Cookson ST, Nora JJ, Kithas JA, Arduino MJ, Bond WW, Miller PH, Monahan J,
Hoffman RE, Curiel TJ, Kaufman D, Groves BM, Jarvis WR. Pyrogenic
reactions in patients undergoing cardiac catheterization associated with
contaminated glass medicine cups. Catheterization and Cardiovascular Diagnosis,
1997;42(1):12-18.
24.
Curiel TJ. Gene therapies for AIDS-related malignancies. Science & Medicine
1997;4(5):4-5.
25.
Kim M, Accavitti MA, Saleh M, Rosenfeld R, Curiel TJ and Curiel DT.
Adenoviral vector mediated delivery of the Herpes Simplex virus thymidine
kinase gene sensitizes EBV-transformed B cell lines to ganciclovir. Tumor
Targeting, 1996;2(4):215-223.
26.
Curiel TJ, Kasano K, Piché A and Curiel DT. Gene therapy strategies for AIDSrelated malignancies. Gene Therapy, 1997;4:1284-88.
27.
Nash PN, Purner MB, Leon RP, Clarke P, Duke RC and Curiel TJ. Toxoplasma
gondii infected cells are resistant to multiple inducers of apoptosis. J. Immunol,
1998;160(4):1824-30.
28.
Berens RL, Krug EC, Nash PB, and Curiel TJ. Selection and characterization of
Toxoplasma gondii mutants resistant to artemisinin. J. Infectious Diseases,
1998;177(4):1128-1131.
29.
Purner MB, Berens RL, Tomavo S, Lecordier L, Cesbron-Delauw MF, Kotzin
BL, Curiel TJ. Stimulation of human T lymphocytes obtained from Toxoplasma
gondii-seronegative persons by proteins derived from T. gondii. J Inf Dis,
1998;177(3):746-753.
30.
Kenney JL, Guinness ME, Curiel T, Lacy J. Antisense to the Epstein-Barr virus
(EBV)-encoded latent membrane protein 1 (LMP-1) suppresses LMP-1 and BCL2 expression and promotes apoptosis in EBV-immortalized B-cells, Blood, 1998;
92(5):1721-1727.
31.
Piché A, Kasono K, Johaning F, Curiel TJ, Curiel DT. Phenotypic knockout of
the latent membrane protein 1 of Epstein-Barr virus by an intracellular singlechain antibody. Gene Therapy, 1998;5:1171-1179.
24
32.
Suzuki T, Piche A, Kasono K, Xiang J, Gomez-Navarro J, Moriuchi S, Krisky
DM, Oligino T, Glorioso JC, Curiel TJ, Curiel DT. Efficient gene delivery into
Epstein-Barr virus (EBV)-transformed human B cells mediated by replicationdefective herpes simplex virus-1 (HSV- 1): A gene therapy model for EBVrelated B cell malignancy. Biochem Biophys Res Commun, 1998;3:686-690.
33.
Tillman BW, de Gruijl TD, Bakker SA, Scheper RJ, Pinedo HM, Curiel TJ,
Gerritsen WR and Curiel DT. Maturation of dendritic cells accompanies highefficiency gene transfer by a CD40-targeted adenoviral vector. J Immunol,
1999;162(11): 6378-6383.
34.
Morgan MB, Goldstein NB, Scadden D, Lacy J, Curiel DT, Curiel TJ. Treatment
of EBV transformed tumors with antisense oligodeoxynucleotides against EBNA1 enhances tumor chemosensitivity. Tumor Targeting, 2000;4:278-286.
35.
Levy MF, Crippin J, Sutton S, Netto G, McCormack J, Curiel TJ, Goldstein RM,
Newman JT, Gonwa TA, Banchereau J, Diamond LE, Byrne G, Logan J, and
Klintmalm G. Liver allotransplantation after extracorporeal hepatic support with
transgenic (hCD55/hCD59) porcine livers. Transplantation, 2000;69(2):272-280.
36.
Zou W-P, Borvak J, Marches F, Wei S, Isaeva T, Curiel TJ. A Guide to Isolation,
Culture and Propagation of Dendritic Cells. In “Dendritic Cells: Biology and
Clinical Applications” Second Edition. MT Lotze and AW Thomson, eds.
Academic Press. London. 2001, pp. 77-96.
37.
Zou W, Borvak J, Marches F, Wei S, Galanaud P, Emilie D, Curiel TJ.
Macrophage-derived dendritic cells have strong Th1-polarizing potential
mediated by β-chemokines rather than IL-12. J Immunol, 2000:165(8):4388-4396.
38.
Zou W, Borvak J, Wei S, Curiel DT, Curiel TJ. Reciprocal regulation of
plasmacytoid dendritic cells and monocytes during viral infection. Eur J Immunol,
2001(31):3833-3839.
39.
Wei S, Marches F, Borvak J, Zou W, Channon J, White M, Radke J, CesbronDelauw M, Curiel TJ. Toxoplasma gondii infected human myeloid dendritic cells
inhibit T lymphocyte activation and induce contact-dependent apoptosis. Infection
and Immunity, 2002;70(4):750-60.
40.
Zou W, Machelon V, Coulomb-L’Hermin A, Borvak J, Nome F, Isaeva T, Wei S,
Krzysiek R, Durand-Gasselin I, Gordon A, Pustilnik T, Curiel DT, Galanaud P,
Capron F, Emilie D, Curiel TJ. Stromal derived factor-1 in human tumors
recruits and alters the function of plasmacytoid precursor dendritic cells. Nature
Medicine, 2001;7(12):1339-1346.
41.
Curiel TJ and Curiel DT. Tumor immunotherapy: Inching towards the finish line.
Journal of Clinical Investigation, 2002;109:311-312.
25
42.
Wei S, Marches F, Daniels B, Sonda S, Heidenreich K, Curiel TJ.
Pyridinylimidazole p38 MAP kinase inhibitory drugs inhibit intracellular
Toxoplasma gondii replication. International Journal for Parasitology, 2002;
32(8):969-77.
43.
Establishment and characterization of a new mantle cell lymphoma cell line, Lai
M, McDonnell T J, O'Connor S L, Medeiros L J, Oudat R, Keating M, Morgan M
B, Curiel TJ, R J Ford 2002; Leukemia Research;26:849-55.
44.
Zou, W. and Curiel TJ. VLA-5 and transendothelial migration. Nature Medicine
2002;8(8):765-766. [letter]
45.
Mudad R, Ramsey M, Kovitz K, Curiel TJ, Hartz R, Nedzi LL, Weiner RS,
Zakris EL: Concomitant weekly docetaxel, cisplatin and radiation therapy in
locally advanced non-small cell lung cancer: A dose finding study. Lung Cancer,
2003;39(2):173-177.
46.
Curiel TJ, Wei S, Dong H, Krzysiek R, Cheng J, Knuston K, Mottram P, Daniel
B, Zimmermann M, Borvak J, Gordon A, Dhurandhar N, Myers L, Berggren R,
Emilie D, Alvarez R D, Hemminki A, Curiel D T, Chen L, Zou W. Myeloid
dendritic cell associated B7-H1 inhibits T cell-mediated anti-tumor immunity.
Nature Medicine, 2003;9(5):562-567.
47.
Kawakami Y, Curiel TJ, Curiel DT. “Cancer Gene Therapy and
Immunotherapy” 2003;Cancer Chemother Biol Response Modif. 21:327-37.
48.
Zou W, Wei S and Curiel TJ. “Dendritic Cells” in Gene Therapy. D. Curiel and
J. Douglas, eds. Blackwell publishing, in press.
49.
Knutson KL, Curiel TJ, Salazar L, Disis ML. “Immunologic Principles and
Immunotherapeutic Approaches in Ovarian Cancer”, Hematology and Oncology
Clinics of North America, 2003;17(4):1051-1073.
50.
La Russa VF, Mondal D, Miller A, Safah H, Rozans M, Curiel TJ, Agrawal K,
Weiner R. Neuronal Stem Cells: Biology and Plasticity. Cancer Investigation,
2003;21(5):780-792.
51.
Pulendran B, Dillon S, Joseph C, Curiel TJ, Banchereau J, M Mohammadzadeh.
Dendritic cells generated in the presence of GM-CSF plus IL-15 prime potent
CD8+ Tc1 responses in vivo. Eur J Immunol, 2004;34(1):66-73.
52.
Bennouna S, Bliss SK, Curiel TJ, Denkers EY. Cross-talk in the innate immune
system: Neutrophils instruct recruitment and activation of dendritic cells during
microbial infection. J Immunol 2003;171:6052-8.
26
53.
Weldon CB, Parker AP, Patten D, Elliot S, Tang Y, Frigo DE, Dugan CM,
Coakley EL, Butler NN, Clayton JL, Alam J, Curiel TJ, Beckman BS, Jaffe BM,
Burow ME. Sensitization of Apoptotically-Resistant Breast Carcinoma Cells to
TNF and TRAIL by Inhibition of P38 Mitogen-Activated Protein Kinase
Signaling. International Journal of Oncology 2004;24(6):1473-1480.
54.
Weldon CB, Elliott S, Zhu Y, Clayton JL, Curiel TJ, Jaffe BM, Burow ME.
Regulation of estrogen-mediated cell survival and proliferation by p160
coactivators. Surgery 2004;136(2):346-354.
55.
Curiel TJ, Cheng P, Mottram P, Alvarez X, Moons L, Evdemon-Hogan M, Wei
S, Zou L, Kryczek I, Hoyle G, Lackner A, Carmeliet P, Zou W. Dendritic cell
subsets differentially regulate angiogenesis in human ovarian cancer. Cancer
Research 2004;64(16):5535-5538.
56.
Curiel TJ, Morris C, Brumlik M, Landry SJ, Finstad K, Nelson A, Joshi V,
Hawkins C, Alarez X, Lackner A, Mohamadzadeh M. Peptides identified through
phage display direct immunogenic antigen to dendritic cells. J Immunol
2004;172(12):7425-31.
57.
Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan
M, Conejo-Garcia JR, Zhang L, Burow M, Zhu Y, Wei S, Daniel B, Gordon A,
Myers L, Disis ML, Knuston K, Lackner A, Chen L, ZouW.. Specific recruitment
of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts
reduced survival Nature Medicine 2004;10(9):942-949. [Featured in News and
Views: Shevach, E.M. Fatal attraction: tumors beckon regulatory T cells. Nat Med
10, 900-901 (2004). Among the most cited papers on human regulatory T cells]
58.
Brumlik M, Wei S, Finstad K, Nesbit J, Hyman LE, Lacey M, Burow ME, Curiel
TJ. Identification of a novel mitogen-activated protein kinase in Toxoplasma
gondii. Intl J Parasitol 2004; 34:1245-1254.
59.
Zou L, Barnett B, Safah H, LaRussa VF, Evdemon-Hogan M, Mottram P, Wei S,
David O, Curiel TJ, Zou W. Bone marrow is a reservoir for CD4+CD25+
regulatory T cells that traffic through CXCL12/CXCR4 signals. Cancer Research,
2004;64(22):8451-8455.
60.
Kryczek I, Lange A, Mottram P, Alvarez X, Cheng P, Hogan M, Moons L, Wei S,
Zou L, Machelon V, Emilie D, Terrassa M, Lackner A, Curiel TJ, Carmeliet P,
Zou W. CXCL12 and vascular endothelial growth factor synergistically induce
neoangiogenesis in human ovarian cancers. Cancer Research, 2005;65:465-472.
61.
Wei S, Kryczek I, Zou L, Curiel TJ, Cheng P, Zou W. Novel tumor
immunotherapy: Targeting dysfunctional antigen presenting cells. Discovery
Medicine, 2005;5(29):489-492
27
62.
Korokhov N, de Gruijl TD, Aldrich WA, Triozzi PL, Banerjee PT, Gillies SD,
Curiel TJ, Douglas JT, Scheper RJ & Curiel DT. High efficiency transduction of
dendritic cells by adenoviral vectors targeted to DC-SIGN. Cancer Biol Ther,
2005;4(3):289-94.
63.
Wei S, Kryczek I, Zou L, Daniel B, Cheng P, Mottram P, Curiel TJ, Lange A,
Zou W. Plasmacytoid dendritic cells induce CD8+ regulatory T cells in human
ovarian carcinoma Cancer Res, 2005;62(12):5020-5026.
64.
Barnett B, Kryczek I, Cheng P, Zou W, Curiel TJ. Regulatory T cells in ovarian
cancer: Biology and therapeutic potential. American Journal of Reproductive
Immunology, 2005:54(6):369-377.
65.
Combe CL, Curiel TJ, Moretto MM, Khan IA. NK cells help to induce CD8(+)T-cell immunity against Toxoplasma gondii in the absence of CD4(+) T cells.
Infect Immun 2005;73(8): 4913-21
66.
Frigo DE, Basu A, Nierth-Simpson E N, Weldon CB, Dugan CM, Elliott S,
Collins-Burow BM, Salvo VA, Zhu Y, Melnik LI, Lopez GN, Kushner PJ, Curiel
TJ, Rowan BG, McLachlan JA, Burow ME. p38 MAPK stimulates estrogenmediated transcription and proliferation through the phosphorylation and
potentiation of the p160 coactivator GRIP1 Molecular Endocrinology,
2006;20(5):971-983.
67.
Zou W and Curiel TJ. “Dendritic cells” in Immunotherapy of Cancer, M. L.
Disis, ed. 2006, Humana Press, pages 115-126.
68.
Kryczek I, Mottram P, Zou L, Curiel TJ, Zou W. A novel population of myeloid
suppressor cells in ovarian cancer mediate immunopathology through B7-H4.
Journal of Experimental Medicine, 2006;203(4):871-881
69.
Rüter J, Barnett BG, Kryczek I, Coukos G, Zou W, Curiel TJ. Manipulating T
regulatory cells in cancer immunotherapy, Expert Opinion in Dermatology, in
press
70.
Berggren RE, Curiel TJ. After the storm--health care infrastructure in postKatrina New Orleans. New England Journal of Medicine 2006; 354;15: 15491552.
71.
Salvo VA, Boue SM, Fonseca JP, Elliott S, Corbitt C, Collins-Burow BM, Curiel
TJ, Srivastav SK, Shih BY, Carter-Wientjes C, Wood CE, Erhardt P, Beckman
BS, McLachlan JA, Cleveland TE, Burow ME. Antiestrogenic glyceollins
suppress human breast and ovarian carcinoma tumorigenesis. Clinical Cancer
Research 2006;12(23): 7159-7164.
28
72.
Curiel TJ. Murder or Mercy? Hurricane Katrina and the Need for Disaster
Training. New England Journal of Medicine, 2006;355(20):2067-2069.
73.
Lacey M, Brumlik MJ, Yenni RE, Burow ME, and Curiel TJ. Toxoplasma gondii
expresses two mitogen-activated protein kinase genes that represent distinct
protozoan subfamilies. J Molec Evolution 2007;64(1):4-14.
74.
Curiel TJ. Regulatory T cell development: Is Foxp3 the decider? Nature Medicine
2007;13(3):250-253.
75.
Rüter J, Barnett BG, Kryczek I, Brumlik MJ, Daniel BJ, Coukos G, Zou W,
Curiel TJ. Altering regulatory T cell function in cancer immunotherapy: A novel means
to boost efficacy. Frontiers in Bioscience, in press
76.
Rüter J, Barnett BG, Kryczek I, Brumlik MJ, Daniel BJ, Coukos G, Zou W,
Curiel TJ. T regulatory cell manipulation in tumor immunotherapy. In: Cancer
Immunotherapy. James Hodge, editor. Academic Press, in press
77.
Curiel TJ. Treg cells and rethinking cancer immunotherapy. Journal of Clinical
Investigation, 2007;117(5):1167-1174.
78.
Mary T. Litzinger, Romaine Fernando, Tyler J. Curiel, Douglas W. Grosenbach,
Jeffrey Schlom, and Claudia Palena. The IL-2 immunotoxin denileukin diftitox
reduces regulatory T cells and enhances vaccine-mediated T-cell immunity, Blood,
2007;110(9): 3192-201
79.
Wei, S., Daniel, B. J., Brumlik, M. J., Burow, M. E., Zou, W., Khan, I. A.,
Wadsworth, S., Siekierka, J., Curiel, T. J. Drugs designed to inhibit human p38
mitogen-activated protein kinase activation treat Toxoplasma gondii and
Encephalitozoon cuniculi infection. Antimicrob Agents Chemother 2008;51(12):
4324-8.
80.
Tang, Y., Zhao, D. Y., Elliott, S., Zhao, W., Curiel, T. J., Beckman, B. S., Burow,
M. E. Epigallocatechin-3 gallate induces growth inhibition and apoptosis in human
breast cancer cells through survivin suppression. Int J Oncol 2007;31(4): 705-11.
81.
Curiel TJ. Regulatory T cells and treatment of cancer. Current Opinion in Immunology
2008, 20:241–246
82.
Barnett BG, Rüter J, Kryczek I, Brumlik MJ, Cheng PJ, Daniel BJ, Coukos G,
Zou W, Curiel TJ. 2008. Regulatory T cells: A New Frontier in Cancer
Immunotherapy. Adv Exp. Med. Bio. 2008;622:255-260.
83.
Coukos, G., W. Zou and T. J. Curiel. “Immune biomarkers” in Prognostic and Predictive
Factors in Gynecologic Cancers, in press
29
84.
Wei, S., Curiel, T., Coukos, G., Liu, R., Zou, W. 2008. Inhibitory B7 family
members in human ovarian carcinoma. Adv Exp Med Biol 622:261-71
85.
Padmanabhan, S., Ravella, S., Curiel, T., Giles, F. Current status of therapy for
chronic myeloid leukemia: a review of drug development 2008. Future Oncol.
4(3):359-77.
86.
Brumlik, M. J., Daniel, B. J., Waehler, R., Curiel, D. T., Giles, F. J., Curiel, T. J.
Trends in immunoconjugate and ligand-receptor based targeting development for
cancer therapy. 2008 Expert Opin Drug Deliv 5(1):87-103.
Manuscripts submitted for publication:
Invited speaking engagements
Moderator:
Immunity to intracellular pathogens. Front Range Workshop "The Host Response
to Infections". Denver, CO, May 16, 1997.
Host-Pathogen Interplay. International Conference on Toxoplasmosis. Freising,
Germany. May 21-25, 2001.
Moderator Session, Clinical Oncology. Southern Society for Clinical
Investigation. New Orleans, LA. February 20-22, 2003.
Session Moderator. Tulane Annual Research Days. April 24-25, 2003. Tulane
Medical School, New Orleans, LA.
Session Co-Chair. Anti-Tumor Effector Cells and Regulation of Tumor
Immunity. American Association of Immunologists Annual Meeting, Denver,
CO. May 6-10, 2003.
Session Chair: Tumor Immunotherapy. International Conference of Cancer
vaccines (co-sponsored by NCI). Bethesda, MD, February 5-7, 2006.
Talks:
1.
2.
3.
4.
5.
6.
CD4+ HIV-1 envelope specific CTL in an HIV infected individual. AIDS Clinical
Trials Group Meeting, Bethesda, MD, September, 1991.
Approaches to determination of CTL activity in recipients of a candidate AIDS
vaccine. AIDS Clinical Trials Group Meeting, Washington, D.C. March, 1992.
Preliminary results of CTL activity in recipients of the Salk HIV vaccine.
National Cooperative Vaccine Development Group Meeting, Chantilly, VA.
September, 1992.
Human Toxoplasmosis. American Association of Veterinary Pathologists Annual
Meeting, Minneapolis, MN. July, 1993.
Human Toxoplasmosis. Miles Seminar on Toxoplasma Vaccine Development.
Kansas City, MO. August 13, 1993.
Toxin gene therapy for HIV disease and cancers. UAB Cancer Center Series,
Birmingham, AL. September 7, 1993.
30
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
Cellular immune responses in HIV disease. AIDS Center, UAB, Birmingham,
AL. September 8, 1993.
Gene therapy for AIDS. Emory University School of Medicine. November 29,
1993.
Human cellular immunity to the intracellular parasite, Toxoplasma gondii.
Immunology lecture series. The National Jewish Center for Immunology and
Respiratory Medicine, Denver, Colorado. January 5, 1994.
Human cellular immunity to Toxoplasma gondii. Emory Medical School,
Infectious Disease research seminar series. June 22, 1994
Toxoplasma gondii elicits poor CD8+ cellular immunity in infected humans.
Immunology seminar sponsored by Alan Sher and Ricardo Gazzinelli, National
Institutes of Health, Bethesda, MD, July 25, 1994.
Antigen presentation by Toxoplasma infected cells. Conference Jacques Gonod,
Escape mechanisms devised by parasites and Mycobacteria: Possible interference.
Aussois, France. September 4-9, 1994.
Human Toxoplasmosis: Clinical disease and occupational risks. Keynote address
(The Litwak Lecture), North Carolina State School of Veterinary Medicine,
Raleigh, NC. September 29, 1994.
Antigen processing and presentation by cells infected with Toxoplasma gondii.
Presenter and round table discussant. Seventh International Congress of
Parasitology, Izmir, Turkey, October 10-14, 1994.
Epstein-Barr virus and tumorigenesis. UAB gene therapy series, Birmingham,
AB. March 24, 1995.
Human cellular immunity to Toxoplasma gondii. Massachusetts General Hospital
Infectious Disease Unit Research Seminars Series, Boston, MA. April 18, 1995.
Toxoplasma gondii infected cells are resistant to multiple inducers of apoptosis.
National Jewish Center for Immunology and Respiratory Medicine, Denver, CO.
Research in Progress Series. November 9, 1995.
Antigen presentation in Toxoplasma gondii infected cells. INSERM, Lille,
France. November 21, 1995. Sponsored by Jean-François Dubremetz.
Emerging infectious diseases. Colorado State Legislature April 10, 1996.
Human cellular immunity to Toxoplasma gondii. Front Range Workshop "The
Host Response to Infections" Denver, CO, May 10, 1996.
Cellular immune response to Toxoplasma gondii in Toxoplasma naive
individuals. Front Range Workshop "The Host Response to Infections". Denver,
CO, May 10, 1996.
T. gondii elicits cellular proliferative responses in naive humans. National Jewish
Center for Immunology and Respiratory Medicine, Denver, CO. Research in
Progress series, October 22, 1996.
Inhibition of EBV transforming genes: insights into viral pathogenesis and
potential treatment strategies. Baylor Institute for Immunology Research, Dallas,
TX. March 25, 1997.
An overview of AIDS-related lymphomas. Rocky Mountain Annual Conference
on HIV Disease. Denver, CO. February 7, 1997.
31
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.
40.
41.
42.
43.
Inhibition of EBV transforming genes: viral pathogenesis and potential for
treatment of transformed tumors. Wayne State Medical School, Detroit, MI. May
12, 1997.
Human cellular immunity to Toxoplasma gondii. Front Range Workshop "The
Host Response to Infections" Denver, CO, May 16, 1997.
Cellular immune response to Toxoplasma gondii in Toxoplasma naive
individuals. Front Range Workshop "The Host Response to Infections". Denver,
CO, May 16, 1997.
T. gondii infection and intracellular stress. Front Range Workshop "The Host
Response to Infections". Denver, CO, May 16, 1997.
HIV infection and the general medicine practitioner. Pueblo Medical Center,
Pueblo, CO. May 23, 1997.
Human T cell-mediated immunity to Toxoplasma gondii. University of Texas,
Southwestern Immunology series. Dallas, TX. May 30, 1997.
Considerations of APCs in vaccine development. Vaccine Research Workshop
sponsored by Pasteur-Connaught-Merieux, Paris, France. October 23-24, 1997.
Dendritic cells in human immune therapy. Transplantation ‘98 Workshop. Dallas,
TX. April 29, 1998.
EORTC Annual meeting. Functional and phenotypic characteristics of human
dendritic cells. Tyler J. Curiel and Jacques Banchereau. Amsterdam, Holland.
June 16, 1998.
Macrophage derived dendritic cells. University of Alabama, Birmingham, Gene
Therapy Dendritic Cell Focus Group Series. January 20, 2000.
Novel effector functions of distinct dendritic cell subsets. University of Colorado
Health Sciences Center, Cancer Center Grand Rounds, Denver, CO. August 16,
2000.
Novel effector functions of distinct dendritic cell subsets. University of Cincinnati
Children’s Medical Center Vaccine Series. August 29, 2000.
DCs induce IL-12-independent Th1 polarization through b-chemokines. UTSW
Oncology Research Program. September 21, 2000.
DCs induce IL-12-independent Th1 polarization through b-chemokines: Potential
clinical applications. Northwest Biopharmaceuticals Research Program.
December 18, 2000.
Functional dendritic cells in the tumor microenvironment. University of New
Mexico School of Medicine. January 22, 2001.
Development of a Comprehensive Cancer Center. Leo W. Jenkins Cancer Center
and East Carolina School of Medicine. February 8, 2001.
Control of plasmacytoid dendritic cell migration and function. Dermatology
Grand Rounds. University of Texas Southwestern School of Medicine. Dallas,
TX. March 8, 2001.
Dendritic cell migration and function in human tumors. Tulane University
Medical School. Special seminar. April 4, 2001.
Functional consequences of dendritic cell migration. Tulane Biochemistry Lecture
Series. September 9, 2001.
Dendritic cell recruitment and function in tumors. Tulane Cancer Center Noon
Seminar Series. October 25, 2001.
32
44.
45.
46.
47.
48.
49.
50.
51.
52.
53.
54.
55.
56.
57.
58.
59.
60.
61.
62.
63.
Factors governing DC migration. Tulane Gene Therapy Center. November 8,
2001.
SDF-1 produced by tumors induces preDC2 to migrate into the tumor
microenvironment, and alters preDC2 function. ChemoCentryx invited seminar.
San Carlos, CA. November 20, 2001.
“MAPK and the control of cell growth: A model using Toxoplasma gondii”
Pharmacology Department, Tulane Medical School. December 14, 2001.
“DCs and tumor immunity”. Presentation to the Tulane Cancer Center Advisory
Board. January 29, 2002
“Dendritic Cells: Armour and Sword of Immunity.” Medical Grand Rounds.
Tulane University Medical Center, New Orleans, LA. January 30, 2002.
“MAPK and control of Toxoplasma gondii replication”. Tulane Molecular and
Cell Biology Program “Chalk Talk” program. February 1, 2002.
“Immunotherapy for ovarian cancer: What do we know?". Obstetrics and
Gynecology Grand Rounds, Tulane Medical School. February 21, 2002.
Dendritic Cells and Tumor Immunity. Tulane Surgery Ground Rounds. March
2002.
p38 MAPK and the control of cell proliferation. Johnson and Johnson Directed
Giving Program Award acceptance speech. Tulane Medical School. March 2002.
Dendritic cell functions and differentiation in human tumors. UAB Cancer Center
Speaker’s Forum. May 5, 2002. Birmingham, AB.
The secret to ultradistance running. Tulane Cancer Center series. September 5,
2002.
Novel insights into the immunopathogenesis of ovarian cancer. Fourth Biennial
International Conference on Ovarian Cancer. September 19, 2002.
p38 MAPK inhibitors and regulation of T. gondii growth. Johnson and Johnson
Infectious Disease Group. October 17, 2002. Raritan, NJ.
Tulane Medical School Medical Grand Rounds. “A 59 year-old man with a lung
mass”. Case discussant. October 30, 2002. New Orleans, LA.
“p38 MAPK inhibitors block replication of T. gondii in vitro and protect fatally
infected mice.” Tulane Cell Signaling Workshop. New Orleans, LA. November
25, 2002.
Update on inhibition of Toxoplasma growth by p38 MAPK inhibitors. Johnson
and Johnson Directed Giving Speakers Convention. Raritan, NJ. December 3,
2002.
“Cancer Gene Therapy in the Twenty-First Century”. Community Issues in
Cancer Management sponsored by Kadlec Medical Center, Richland, WA. March
21, 2003.
“Tumor immunology and clinical implications” New Orleans Medical
Symposium. New Orleans, LA. April 4, 2003.
“Career choices in Academic Medicine”. Noon lecture to Tulane housestaff, May
2003.
Zou W and Curiel TJ. Blockade of B7-H1 pathway improves myeloid dendritic
cell-mediated anti-tumor immunity. Abstract Number: 3008. American
Association of Immunologists Annual Meeting, Denver, CO. May 4-8, 2003.
33
64.
65.
66.
67.
68.
69.
70.
71.
72.
73.
74.
75.
76.
77.
78.
79.
80.
81.
82.
Brumlik MJ, Wei S, Burow ME, and Curiel TJ. Identification of gene encoding a
novel mitogen-activated protein kinase in Toxoplasma gondii. American Society
for Microbiology Southern Meeting, October 23, 2003, New Orleans, LA.
“Tumor Immunotherapy: Progress and Problems”. Medical Grand Rounds.
Tulane Medical School, February 18, 2004.
“Cancer Immunotherapy”. Noon Tulane Medical Residents lecture. Tulane
Medical School, New Orleans, LA. March 4, 2004.
Brumlik M, Wei S, Lacey M, Curiel TJ. Identification of a novel T. gondii MAP
kinase. Keystone Symposium “The Host-Pathogen Standoff”. Taos, NM, March
26-30, 2004.
Treg trafficking. “The Host-Pathogen Standoff
“A History of Immunotherapy”. C. Thorpe Ray Society Annual Lectureship. New
Orleans, LA. March 23, 2004.
“Statistical analysis of clinical trials”. Noon lecture to Tulane Medical Oncology
Fellows. Tulane Medical School, New Orleans, LA. April 6, 2004.
Zou W, Curiel TJ. “Specific recruitment of regulatory T cells fosters immune
privilege in ovarian carcinoma” Abstract Number 8380. FASEB Meeting April
17-21, Wash, DC 2004.
Weldon CB, Elliott S, Zhu Y, Clayton JL, Curiel TJ, Jaffee BM, Burow ME.
Regulation of Estrogen-mediated Cell Survival by p160 coactivators. Society of
University Surgeons, February 13, 2004, St. Louis, MO.
Novel MAPK family members and their activation in T. gondii. Visiting scientist,
Scios Corporation, San Francisco, CA. August 25, 2004.
Barnett B and Curiel TJ. Regulatory T cell depletion in human cancer. Marsha
Rivkin Biennial Ovarian Cancer Research Symposium. September 25, 2004.
Seattle, WA.
“When bad things happen to good cells”. Tulane 170th anniversary celebration.
Key note address. October 1, 2004. Tulane University, New Orleans, LA.
Zou W and Curiel TJ. “Cancer: When bad things happen to good cells.”
Mauvernay Grand Prize address. Tulane University, New Orleans, LA.
Novel immune-based treatments for ovarian cancer. Vermont Cancer Center
Grand Rounds. Burlington, VT. October 13, 2004.
AIDS-related malignancies. Vermont Cancer Center Visiting Professor Rounds.
Burlington, VT. October 13, 2004.
Biologic agents to treat cancer. 98th Annual Meeting of the Southern Medical
Association. New Orleans, LA November 11, 2004.
Eighth Annual Douglas L. Gordon Memorial Lecture. “Balancing family and
career in academic medicine”. 22nd Annual Louisiana Chapter of the American
College of Physicians ACP Associates Meeting, January 20, 2005. New Orleans,
LA.
Curiel TJ. Febrile neutropenia. Fellow noon lecture series. Tulane Medical
School. February 7, 2005, New Orleans, LA
Curiel TJ. Treg depletion as a novel anti-cancer strategy. National Cancer
Institute, Jeffrey Schlom Lab Meeting, February 24, 2005.
34
83.
84.
85.
86.
87.
88.
89.
90.
91.
92.
93.
94.
95.
96.
97.
98.
Barnett B and Curiel TJ. Depleting regulatory T cells is associated with
improved immunity and tumor clearance in human cancer. Southern Society of
Clinical Medicine Annual Meeting. New Orleans, LA. February 25, 2005
Brumlik MJ, Wei S, Lacey M, and Curiel TJ. Toxoplasma gondii expresses two
distinct mitogen activated protein kinase genes that are differentially regulated.
Southern Society of Clinical Medicine Annual Meeting. New Orleans, LA.
February 25, 2005
Medical Grand Rounds, Columbia University and Rockefeller University
Distinguished Lectureship in Immunology series. New York, NY. March 3, 2005.
Zou W and Curiel TJ. Novel mechanisms of immune dysfunction in cancer.
Keystone Symposium on tumor immunity. March 10, 2005. Keystone, CO.
Cancer Center Grand Rounds. Memorial Sloan-Kettering Cancer Center. New
York, NY. March 28, 2005.
Curiel TJ. Basketballs, science and lofty career goals. Key note address, Alpha
Omega Alpha Honor Medical Society Louisiana Alpha Chapter. New Orleans,
LA. March 31, 2005.
Barnett B, Kryczek I, Wei S, Cheng P, Zou W, Curiel TJ. Ontak depletes
functional CD4+CD25+ regulatory T cells in association with improved immunity
and tumor clearance in human cancer. Abstract 3226, American Association of
Immunologists Annual Meeting, April 2-7, 2005, San Diego, CA.
Curiel TJ. Phase I/II trial of Ontak to deplete regulatory T cells in human cancer:
an update. Ligand Pharmaceuticals, San Diego, CA. April 5, 2005.
Brumlik M and Curiel TJ. Initial characterization of TgMAPK-1, a novel
mitogen-activated protein kinase in Toxoplasma gondii. Keystone Symposium on
Parasite Drug Development, Copper Mountain, CO, April 9-13, 2005.
Barnett B, and Curiel TJ. Depleting regulatory T cells is associated with
improved immunity and tumor clearance in human cancer. 2005 American
Association for Cancer Research Annual Meeting, Mini-Symposium on Tumor
Immunotherapy. Anaheim, California April 16, 2005. Abstract Number 2655.
Tyler J. Curiel. Regulatory and effector T cells in cancer. Symposium on antitumor immunity. 2005 American Association for Cancer Research Annual
Meeting, Anaheim, California April 16, 2005.
Tyler J. Curiel. Regulatory T cells as novel immunotherapy targets. Cancer
Center Grand Rounds. University of Colorado Health Sciences Center Cancer
Center, Aurora, CO. May 13, 2005.
Tyler J. Curiel. Regulatory T cells as targets for novel cancer immunotherapy.
Alexion Pharmaceuticals Strategic Retreat, Del Mar, CA, May 18, 2005.
Tyler J. Curiel. Regulatory T cells in ovarian cancer: Biology and therapeutic
implications. Plenary talk at the American Society for Reproductive Immunology,
Providence Rhode Island, June 17, 2005.
Tyler J. Curiel. The immunopathogenesis of hepatitis C virus infection. Plenary
address. Seventh International Symposium on Cytokines and Chemokines,
Montreal, Quebec, Canada, September 8, 2005. (cancelled due to Hurricane
Katrina)
Tyler J. Curiel. Therapeutic potential of Tregs in cancer. GlobeImmune. Aurora,
CO, September 27, 2005.
35
99.
100.
101.
102.
103.
104.
105.
106.
107.
108.
109.
110.
111.
112.
113.
114.
115.
116.
Tyler J. Curiel. Regulatory T cells in ovarian cancer: Biology and therapeutic
implications. Keynote speaker. Fall Southwest Oncology Group (SWOG)
meeting, September 30, 2005, New Orleans, LA. (cancelled due to Hurricane
Katrina)
Tyler J. Curiel. Regulatory T cells in cancer. Plenary address. Cancer Research
Institute XIII Annual Meeting on Cancer vaccines. New York, NY, October 6,
2005.
Tyler J. Curiel. Regulatory T cells in ovarian cancer. Visiting Professor address
at Rush Medical School, Chicago, IL. November 27, 2005.
Curiel TJ and Berggren RE. An inside look at Tulane and Charity Hospitals
during Hurricane Katrina. Evergreen Rotary Club Meeting. Evergreen, Colorado.
November 2005.
Tyler J. Curiel. Surviving Katrina: Lessons Learned? Keynote Speaker.
University of Colorado Health Sciences Center Symposium on Biomarkers in
Prostate Cancer. December 9, 2005. Inverness, Colorado.
Curiel TJ and Berggren RE. Medical professionalism and personal preparedness
during Hurricane Katrina. Medical Ground Rounds. Colorado Springs, Colorado.
December 22, 2005.
Tyler J. Curiel. Chemokines in Cancer. Major invited speaker. Keystone
Symposium on Chemokines and Chemokine receptors. Snowbird, UT, January
15-20, 2006.
Tyler J. Curiel. Regulatory T cell depletion as a novel anti-cancer strategy.
International Symposium on Cancer Vaccines. February 5-7, 2006. Washington,
DC.
Tyler J. Curiel. Cancer Immunopathology. Cancer Center Grand Rounds.
University of Colorado Anschutz Cancer Center, Aurora, CO. February 21, 2006.
Tyler J. Curiel. T regulatory cells in cancer. National Jewish Hospital
Immunology Series. March 15, 2006, Denver, CO.
T. J. Curiel. Current status of Ontak to deplete human regulatory T cells. FDA
special panel meeting. Bethesda, MD, March 31, 2006.
Barnett B and Curiel TJ. Phase II clinical trial of ONTAK in advanced-phase
ovarian cancer. AACR Annual Meeting, Washington, DC, April 4, 2006
Tyler J. Curiel. Overcoming obstacles to success. Keynote address. Ursuline
Academy Athletic Department Banquet. May 3, 2006. New Orleans, LA.
Barnett B and Curiel TJ. Phase II trial of Denileukin diftitox to treat advanced
stage ovarian cancer. ASCO annual meeting, June 2-6, 2006, Atlanta, GA.
Tyler J. Curiel. Regulatory T cells in ovarian cancer. International Symposium
on Ovarian Cancer. Crete. June 26-30, 2006.
Tyler J. Curiel. Regulatory T cells in tumor immunopathology. UTHSCSA
Hematology lecture series. September 19, 2006.
Tyler J. Curiel. AIDS related malignancies. 9/28/06. Fellow lecture series.
UTHSCSA.
Tyler J. Curiel. Delivering medical care in a disaster: inside Tulane and Charity
Hospitals during the aftermath of Hurricane Katrina. International Health Club,
UTHSCSA. 9/29/06
36
116.
117.
118.
119.
120.
121.
122.
123.
124.
125.
126.
127.
128.
129.
131.
132.
133.
134.
135.
Tyler J. Curiel. Novel insights into tumor immunopathology. UTHSCSA
Medical Grand Rounds. October 18, 2006
Tyler J. Curiel. Ethical decision making in the immediate aftermath of Hurricane
Katrina. Conference on Bioethical Decision-Making in Disasters for Area Health
Education Consortium (AHEC) in Charleston, SC. Octrober 27, 2006.
Tyler J. Curiel. Regulatory T cells in cancer. 18th EORTC-NCI-AACR
Symposium on Molecular Targets and Cancer Therapeutics, Workshop on
"Overcoming critical barriers in immunotherapy". Prague, Czech Republic.
November 7-10, 2006.
Tyler J. Curiel. The importance of science. Johnson and Johnson Focused Giving
Program, New Brunswick, NJ, November 28, 2006. Featured scientist.
Tyler J. Curiel. Tumor immunotherapy. UTHSCSA Immunology series.
December 8, 2006.
Tyler J. Curiel. “Managing Career Development and Team Building in Clinical
and Translational Research”. Seminar Series for UTHSCSA Scholars Program.
San Antonio, TX.
Tyler J. Curiel “New Concepts in Tumor Immunotherapy” Cellular and
Structural Biology Seminar Series, UTHSCSA. January 9, 2007.
TJ Curiel. “Regulatory T cells in ovarian cancer”. Fourth Biennial Meeting on
Mechanism and Therapeutic Reversal of Immune Suppression in Cancer. January
28, 2007. Tampa Florida.
TJ Curiel. Developing new drugs for tumor immunotherapy. CTRC phase I drug
discovery program. February 21, 2007. San Antonio, TX.
TJ Curiel. Depleting immunoregulatory cells as novel cancer immunotherapy.
Sidney Kimmel Cancer Center Symposium. Key Note Speaker. San Diego, CA.
March 4-7, 2007.
TJ Curiel. Novel approaches to tumor immunotherapy. Visiting professor.
University of Oklahoma Cancer Center. March 14, 2007
TJ Curiel. Mechanisms of tumor-specific immune tolerance. Featured speaker.
World Immune Regulation Meeting. Davos, Switzerland. April 15, 2007.
TJ Curiel. New approaches to tumor immunotherapy: novel insights. The Robert
and Alma Moreton Lectureship in Oncology. Scott and White Medical Center,
Temple, TX. June 15, 2007.
TJ Curiel. Novel approaches to immune therapy based on
recent insights. Eisai Pharmaceuticals visiting scientist. Andover, MA. June 21,
2007.
TJ Curiel. Rethinking tumor immunotherapy: New insights from recent
discoveries. Aspen Cancer Conference, Aspen, CO. July 18, 2007.
TJ Curiel. Disaster preparedness for health care providers: Lessons from
Hurricane Katrina. Florence, SC. July 30, 2007.
TJ Curiel. Treatment options in Melanoma. Imidex Lecture series. August 1,
2007 Houston, TX.
TJ Curiel. Immunotherapy for Melanoma Imidex Lecture series. August 29,
2007. Denver, CO
TJ Curiel. Disaster preparedness for health care providers: Lessons from
Hurricane Katrina, Iowa, September 15, 2007.
37
136.
137.
138.
139.
140.
141.
142.
143.
144.
145.
146.
147.
148.
149.
TJ Curiel. Mechanisms of tumor specific tolerance. UTHSCSA Pharmacology
lecture series. San Antonio, TX. October 31, 2007.
TJ Curiel. Clinical and immunologic experience with Treg depletion:
How can we improve? Eisai Ontak Summit. Princeton, NJ. January 25, 2008.
TJ Curiel. Advances in Tumor Immunotherapy. UTHSCSA Biochemistry
seminar series. February 2008.
TJ Curiel Regulatory T cells as a barrier to cancer immunotherapy. UAB
Department of Gene Therapy and Comprehensive Cancer Center Combined Guest
Lecture Series. March 3, 2008. Birmingham, AL.
TJ Curiel. Regulatory T cells as targets for cancer immunotherapy. CCIR
distinguished lecture seminar series at the MD Anderson Cancer Center. Houston,
TX. April 11, 2008.
TJ Curiel. Crisis leadership: My Katrina experience. Jewish Community Center
Leadership Lecture Series. San Antonio, TX. April 16, 2008.
TJ Curiel. Regulatory T cells and Tumor Immunotherapy. NCI Tumor
Immunology Series, Fredericksburg, MD. May 2, 2008
TJ Curiel. Failure as Success. St. Mary’s Hall Commencement address. May 28,
2008. San Antonio, TX.
TJ Curiel. Immune Dysregulation in Tumors: Its Basis & Means to Overcome It.
June 6, 2008. ACVIM Annual Meeting. State-of-the-Art Lecture Series. San
Antonio, TX.
TJ Curiel. Novel Insights into Tumor Immunity Predict Novel Approaches to
Successful Immunotherapy. ACVIM Annual Meeting. State-of-the-Art Lecture
Series. June 6, 2008. San Antonio, TX.
TJ Curiel. Regulatory T cells and cancer immunotherapy. Laboratori de Recerca
Traslacional Institut Català d´Oncologia Barcelona, SPAIN. June 18, 2008.
TJ Curiel. Regulatory T cells in cancer treatment. Aspen Cancer Conference.
Aspen, CO. July 20, 2008.
Curiel, TJ, “Managing regulatory T cells as a novel cancer treatment strategy”
China Tregs 2008 Conference, Beijing, PRC, October 2008. (featured speaker)
Curiel, TJ, “Regulatory T Cells and Cancer Immunotherapy” UTSW Simmons
Comprehensive Cancer Center Grand Rounds, Dallas, TX, November 2008
(visiting professor)
Upcoming Invited Talks
Atlanta
Shawna Wall, Duane Jeansonne, Pei-Yi Lin, Aijie Liu, Gaby Rennebeck, Suzanne Thibodeaux,
Carolina Livi, Ben Daniel, Tyler Curiel. Effects of Interferon-alpha on Regulatory T-cell Depletion
in Cancer Immunotherapy. Cytokines 2008. Seventh joint conference of the International Society
for Interferon and Cytokine Research and International Cytokine Society. Montreal, Canada.
October 12-16, 2008. Abstract number PP11-340.
,
38
39